Systemic NKT cell deficiency in NOD mice is not detected in peripheral blood: Implications for human studies

Immunology and Cell Biology

Volumn 82, Issue 3, 2004, Pages 247-252

  Berzins, Stuart P ^a   Kyparissoudis, Kon ^a   Pellicci, Daniel G ^a   Hammond, Kristen J ^a   Sidobre, Stephane ^a   Baxter, Alan ^a   Smyth, Mark J ^a   Kronenberg, Mitchell ^a   Godfrey, Dale I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Blood; Natural killer T cell; NOD mouse; Tolerance; Type 1 diabetes

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CELL ASSAY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SIMULATION; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PREDICTION;

ANIMALS; BLOOD; DIABETES MELLITUS, TYPE 1; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; ORGAN SPECIFICITY; T-LYMPHOCYTES;

ANIMALIA;

EID: 3042720630     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2004.01238.x     Document Type: Article

References (30)

1. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol. Today 2000; 21: 573.
2. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2002; 2: 557.
3. MacDonald HR. Development and selection of NKT cells. Curr. Opin. Immunol. 2002; 14: 250.
4. Chatenoud L. Do NKT cells control autoimmunity? J. Clin. Invest. 2002; 110: 747.
5. Baxter AG, Kinder SJ, Hammond KJ, Scollay R, Godfrey DI. Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997; 46: 572.
6. Beaudoin L, Laloux V, Novak J, Lucas B, Lehuen A. NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells. Immunity 2002; 17: 725.
7. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nat. Med. 1999; 5: 601.
8. Lehuen AO, Lantz L, Beaudoin V et al. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. J. Exp. Med. 1998; 188: 1831.
9. Berzins SP, Venanzi ES, Benoist C, Mathis D. T-cell compartments of prediabetic NOD mice. Diabetes 2003; 52: 327.
10. Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 2001; 194: 313.
11. Sharif SGA, Arreaza P, Zucker QS et al. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 2001; 7: 1057.
12. Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. Early quantitative and functional deficiency of NK1+- like thymocytes in the NOD mouse. Eur. J. Immunol. 1996; 26: 2989.
13. Yang Y, Bao M, Yoon JW. Intrinsic defects in the T-cell lineage results in natural killer T-cell deficiency and the development of diabetes in the nonobese diabetic mouse. Diabetes 2001; 50: 2691.
14. Hammond KJ, Pellicci DG, Poulton LD et al. CD1d-restricted NKT cells: an interstrain comparison. J. Immunol. 2001; 167: 1164.
15. Naumov YN, Bahjat KS, Gausling R et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc. Natl Acad. Sci. USA 2001; 98: 13 838.
16. Hammond KJL, Poulton LD, Palmisano LJ, Silveira PA, Godfrey DI, Baxter AG. Alpha/beta-T cell receptor (TCR) +CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD) /Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J. Exp. Med. 1998; 187: 1047.
17. Hong SMT, Wilson I, Serizawa L et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 2001; 7: 1052.
18. Wilson SB, Kent SC, Patton KT et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391: 177.
19. Kukreja AG, Cost J, Marker C et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 2002; 109: 131.
20. Wilson SB, Kent SC, Horton HF et al. Multiple differences in gene expression in regulatory Valpha 24Jalpha Q T cells from identical twins discordant for type I diabetes. Proc. Natl Acad. Sci. USA 2000; 97: 7411.
21. Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J. Clin. Invest. 2002; 110: 793.
22. Oikawa YA, Shimada S, Yamada Y et al. High frequency of valpha24(+) vbeta11(+) T-cells observed in type 1 diabetes. Diabetes Care 2002; 25: 1818.
23. Hammond KJ, Pelikan SB, Crowe NY et al. NKT cells are phenotypically and functionally diverse. Eur. J. Immunol. 1999; 29: 3768.
24. Faunce DE, Sonoda KH, Stein-Streilein J. MIP-2 recruits NKT cells to the spleen during tolerance induction. J. Immunol. 2001; 166: 313.
25. Sonoda KH, Exley M, Snapper S, Balk SP, Stein-Streilein J. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med. 1999; 190: 1215.
26. Matsuda JL, Naidenko OV, Gapin L et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 2000; 192: 741.
27. Benlagha K, Weiss A, Beavis A, Teyton L, Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 2000; 191: 1895.
28. Godfrey DI, Kinder SJ, Silvera P, Baxter AG. Flow cytometric study of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- thymocytes. J. Autoimmun. 1997; 10: 279.
29. Lee PT, Benlagha K, Teyton L, Bendelac A. Distinct functional lineages of human V (alpha) 24 natural killer T cells. J. Exp. Med. 2002; 195: 637.
30. Araki M, Kondo T, Gumperz JE, Brenner MB, Miyake S, Yamamura T. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int. Immunol. 2003; 15: 279.